期刊文献+

麝香通心滴丸联合体外反搏治疗不稳定型心绞痛的疗效观察 被引量:2

下载PDF
导出
摘要 目的观察麝香通心滴丸联合体外反搏治疗不稳定型心绞痛的临床疗效。方法选取我院2018年10月至2020年10月期间收治的120例不稳定型心绞痛住院患者为研究对象,随机分成观察组(n=58)和对照组(n=62)。两组均给予基础治疗,对照组加用麝香通心滴丸,观察组在对照组的基础上联合体外反搏治疗,治疗时程为1个月。比较两组心绞痛症状、心电图、6min步行距离(6MWD)、射血分数(EF)的变化。结果观察组治疗后心绞痛的疗效有效率为94.83%,对照组治疗后心绞痛的疗效有效率为80.65%,观察组心绞痛的疗效有效率优于对照组,差异有统计学意义(P<0.05);观察组及对照组治疗前心绞痛的发作频率、持续时间、6MWD比较,差异无统计学意义(P>0.05),观察组治疗后心绞痛的发作频率、持续时间、6MWD均优于对照组,差异有统计学意义(P<0.05);观察组及对照组治疗后两组心电图的疗效、EF比较,差异无统计学意义(P>0.05)。结论麝香通心滴丸联合体外反搏治疗可明显缓解心绞痛发作,提高运动耐量。
作者 雷刚
机构地区 衡阳市中心医院
出处 《心血管病防治知识(学术版)》 2021年第19期18-20,共3页 Prevention and Treatment of Cardiovascular Disease
基金 衡阳市科技计划项目资助课题(2019jh011129)。
  • 相关文献

参考文献3

二级参考文献49

  • 1李小鹰.阿司匹林在动脉硬化性心血管疾病中的临床应用:中国专家共识(2005)[J].中华心血管病杂志,2006,34(3):281-284. 被引量:194
  • 2Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines(Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol,2002, 40(7) :1366-1374.
  • 3Bertrand ME, Simoons ML, Fox KA, et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J,2002,23 ( 23 ) : 1809 -1840.
  • 4Erhardt L, Herlitz J, Bossaert L, et al. Task force on the management of chest pain. Eur Heart J, 2002, 23 ( 15 ) : 1153-1176.
  • 5CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet, 1996, 348(9038) :1329-1339.
  • 6Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med, 2001 , 345 ( 7 ) :494-502.
  • 7Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet, 2001, 358(9281):527-533.
  • 8Simoons ML, GUSTO IV-ACS Investigators. Effect of glycopmtein Ⅱb/Ⅲa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation:the GUSTO IV-ACS randomised trial. Lancet, 2001,357(9272) :1915-1924.
  • 9Platlat Receptor Inhibitor in Ischemic Syndrome Management(PRISM) study investigator. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management ( PRISM )Study Investigators. N Engl J Med, 1998, 338(21 ) :1498-1505.
  • 10Platlat Receptor Inhibitor in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms(PRISM-PLUS) study investigator. Inhibition of the platelet giycoprotein Ⅱb/Ⅲa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N Engl J Med,1998, 338(21) :1488-1497.

共引文献2200

同被引文献93

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部